Now available KOMZIFTI™

KOMZIFTI™ (ziftomenib) is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.

Please see full prescribing information here.